LXRX Lexicon Pharmaceuticals Inc
Price (delayed)
$0.6718
Market cap
$242.85M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.63
Enterprise value
$276.49M
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes
Highlights
The company's EPS rose by 21% YoY and by 16% QoQ
Lexicon Pharmaceuticals's gross margin has increased by 5% YoY and by 4.8% from the previous quarter
Lexicon Pharmaceuticals's equity has surged by 57% YoY but it has decreased by 18% QoQ
The net income has decreased by 13% YoY but it has increased by 7% from the previous quarter
Lexicon Pharmaceuticals's quick ratio has decreased by 26% from the previous quarter
Key stats
What are the main financial stats of LXRX
Market
Valuations
Earnings
Shares outstanding
361.49M
Market cap
$242.85M
Enterprise value
$276.49M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.66
Price to sales (P/S)
6.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.9
Revenue
$31.08M
Gross profit
$30.47M
Operating income
-$197.12M
Net income
-$200.4M
EBIT
-$184.82M
EBITDA
-$184.29M
Free cash flow
-$179.81M
Per share
Balance sheet
Liquidity
EPS
-$0.63
EPS diluted
-$0.63
Free cash flow per share
-$0.56
Book value per share
$0.4
Revenue per share
$0.1
TBVPS
$0.79
Total assets
$298.42M
Total liabilities
$152.47M
Debt
$100.3M
Equity
$145.95M
Working capital
$200.95M
Debt to equity
0.69
Current ratio
5.44
Quick ratio
5.34
Net debt/EBITDA
-0.18
Margins
Efficiency
Dividend
EBITDA margin
-592.9%
Gross margin
98%
Net margin
-644.8%
Operating margin
-634.2%
Return on assets
-56.8%
Return on equity
-93.9%
Return on invested capital
-58.2%
Return on capital employed
-73%
Return on sales
-594.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LXRX stock price
How has the Lexicon Pharmaceuticals stock price performed over time
Intraday
5.38%
1 week
34.36%
1 month
84.97%
1 year
-58.27%
YTD
-9.03%
QTD
45.79%
Financial performance
How have Lexicon Pharmaceuticals's revenue and profit performed over time
Revenue
$31.08M
Gross profit
$30.47M
Operating income
-$197.12M
Net income
-$200.4M
Gross margin
98%
Net margin
-644.8%
LXRX's operating margin has surged by 96% year-on-year and by 84% since the previous quarter
LXRX's net margin has surged by 96% year-on-year and by 84% since the previous quarter
The operating income has declined by 15% year-on-year but it has grown by 7% since the previous quarter
The net income has decreased by 13% YoY but it has increased by 7% from the previous quarter
Growth
What is Lexicon Pharmaceuticals's growth rate over time
Valuation
What is Lexicon Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.66
P/S
6.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.9
The company's EPS rose by 21% YoY and by 16% QoQ
Lexicon Pharmaceuticals's equity has surged by 57% YoY but it has decreased by 18% QoQ
The P/B is 51% lower than the 5-year quarterly average of 3.4 and 25% lower than the last 4 quarters average of 2.2
LXRX's price to sales (P/S) is 99% less than its 5-year quarterly average of 991.5 and 95% less than its last 4 quarters average of 128.6
Efficiency
How efficient is Lexicon Pharmaceuticals business performance
The company's return on sales has surged by 96% YoY and by 84% QoQ
The company's return on equity rose by 33% YoY and by 13% QoQ
LXRX's ROA is up by 21% YoY and by 12% QoQ
LXRX's ROIC is up by 21% YoY and by 8% from the previous quarter
Dividends
What is LXRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LXRX.
Financial health
How did Lexicon Pharmaceuticals financials performed over time
The total assets is 96% greater than the total liabilities
The total assets has grown by 30% year-on-year but it has declined by 7% since the previous quarter
The current ratio has contracted by 27% from the previous quarter and by 2.9% YoY
LXRX's debt is 31% smaller than its equity
Lexicon Pharmaceuticals's equity has surged by 57% YoY but it has decreased by 18% QoQ
Lexicon Pharmaceuticals's debt to equity has decreased by 36% YoY but it has increased by 23% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.